Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus FLOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus FLOXIN.
CIPROFLOXACIN HYDROCHLORIDE vs FLOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Inhibition of bacterial DNA gyrase and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
500-750 mg orally every 12 hours; 400 mg intravenously every 8-12 hours.
400 mg orally every 12 hours for 10-14 days; ophthalmic solution: 1-2 drops in affected eye(s) every 2-4 hours for 2 days, then 1-2 drops 4 times daily for 10 days; otic solution: 5-10 drops in affected ear(s) twice daily for 10-14 days.
None Documented
None Documented
Terminal half-life 4 hours (3-5 h) in normal renal function; prolonged to 5-10 h in mild-to-moderate renal impairment and >10 h in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life of 10-14 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe cases).
Renal: 50-70% unchanged drug; biliary/fecal: 15-25% (partly as metabolites).
Approximately 70-90% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10-30% eliminated in feces via biliary excretion.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic